Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?

Abstract

The strength of the GEC test appears to lie in its ability to reclassify 42% of indeterminate cytology cases as benign, thereby decreasing the number of unnecessary surgical procedures.